Price (90d)
$3.95Signal Score (90d)
95Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.88B | $-534.51M | $-5.07 |
| 2024 | $2.55B | $-61.62M | $-0.81 |
| 2023 | $1.96B | $-113.04M | $-1.28 |
| 2022 | $1.35B | $-19.16M | $-0.20 |
| 2021 | $907.96M | $-37.60M | $-0.36 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $0.07 per share
Typical surprise -33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.02 vs $-0.01beat
- Thu, May 7$-0.02 vs $-0.05beat
- Tue, Feb 24$0.08 vs $0.06beat
- Thu, Nov 6$0.05 vs $0.10miss
- Thu, Aug 7$-0.10 vs $0.09miss
- Thu, May 8$0.06 vs $0.09miss
Estimates and results for EVH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
EVHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsseekingalpha.com·2d ago·Neutral
Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term debt and persistent GAAP losses. Management projects >25% revenue growth and adjusted EBITDA ≥$150m in 2027, aiming to improve leverage and capital structure.
View source ↗ - Newsmarketbeat.com·7d ago·Neutral
Evolent Health Q2 Earnings Call Highlights Evolent Health NYSE: EVH reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business.
View source ↗